Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure

The Lancet

Volumn 389, Issue 10081, 2017, Pages 1831-1840

  Packer, Milton ^a   McMurray, John J V ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; PEPTIDE; RENIN ANGIOTENSIN SYSTEM INHIBITOR; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR; NEUROPEPTIDE; PEPTIDE HORMONE; PROSTAGLANDIN;

COMPARATIVE EFFECTIVENESS; DRUG EFFECT; ENZYME INHIBITION; HEART FAILURE; HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HUMANS; NEPRILYSIN; NEUROPEPTIDES; PEPTIDE HORMONES; PROSTAGLANDINS; RENIN-ANGIOTENSIN SYSTEM; VASOPEPTIDASE INHIBITORS;

EID: 85007440122     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30969-2     Document Type: Review

References (172)

1. 1 Packer, M, Pathophysiology of chronic heart failure. Lancet 340 (1992), 88–92.
2. 2 Gradman, AH, Papademetriou, V, Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. Am Heart J 157:suppl (2009), S17–S23.
3. 3 Xu, J, Carretero, OA, Liao, TD, et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 299 (2010), H1328–H1338.
4. 4 Patel, BM, Mehta, AA, Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur J Pharmacol 697 (2012), 1–12.
5. 5 Yoshida, H, Takahashi, M, Tanonaka, K, Maki, T, Nasa, Y, Takeo, S, Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Br J Pharmacol 134 (2001), 150–160.
6. 6 Garg, R, Yusuf, S, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995), 1450–1456.
7. 7 Erhardt, LR, A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. Int J Clin Pract 59 (2005), 571–578.
8. 8 McMurray, JJ, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
9. 9 Heran, BS, Musini, VM, Bassett, K, Taylor, RS, Wright, JM, Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev, 4, 2012 CD003040.
10. 10 Angiotensin II receptor antagonists and heart failure: angiotensin-converting enzyme inhibitors remain the first-line option. Prescrire Int 14 (2005), 180–186.
11. 11 Abdulla, J, Abildstrom, SZ, Christensen, E, Kober, L, Torp-Pedersen, C, A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail 6 (2004), 927–935.
12. 12 O'Meara, E, Solomon, S, McMurray, J, et al. Effect of candesartan on New York Heart Association functional class. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 25 (2004), 1920–1926.
13. 13 Cohn, JN, Johnson, G, Ziesche, S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991), 303–310.
14. 14 Gundersen, T, Swedberg, K, Amtorp, O, Remes, J, Nilsson, B, Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group. Eur Heart J 15 (1994), 1659–1665.
15. 15 Jorde, UP, Ennezat, PV, Lisker, J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101 (2000), 844–846.
16. 16 Struthers, AD, Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 2 (1996), 47–54.
17. 17 Athyros, VG, Mikhailidis, DP, Kakafika, AI, Tziomalos, K, Karagiannis, A, Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother 8 (2007), 529–535.
18. 18 van de Wal, RM, Plokker, HW, Lok, DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106 (2006), 367–372.
19. 19 Roig, E, Perez-Villa, F, Morales, M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21 (2000), 53–57.
20. 20 Phillips, CO, Kashani, A, Ko, DK, Francis, G, Krumholz, HM, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167 (2007), 1930–1936.
21. 21 Lakhdar, R, Al-Mallah, MH, Lanfear, DE, Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14 (2008), 181–188.
22. 22 Makani, H, Bangalore, S, Desouza, KA, Shah, A, Messerli, FH, Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, 346, 2013, f360.
23. 23 Gheorghiade, M, Böhm, M, Greene, SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309 (2013), 1125–1135.
24. 24 McMurray, JJ, Krum, H, Abraham, WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374 (2016), 1521–1532.
25. 25 Packer, M, Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation 77 (1988), I64–I73.
26. 26 Dzau, VJ, Packer, M, Lilly, LS, Swartz, SL, Hollenberg, NK, Williams, GH, Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310 (1984), 347–352.
27. 27 Packer, M, Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol 60 (1987), 179–184.
28. 28 Packer, M, Lee, WH, Kessler, PD, Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 74 (1986), 766–774.
29. 29 Kastner, PR, Hall, JE, Guyton, AC, Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol 243 (1982), F260–F264.
30. 30 Kubo, SH, Clark, M, Laragh, JH, Borer, JS, Cody, RJ, Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol 60 (1987), 1322–1328.
31. 31 Lee, ME, Thrasher, TN, Ramsay, DJ, Mechanism of inhibition of renin secretion by increased left atrial pressure. Am J Physiol 248 (1985), R641–R644.
32. 32 Scheuer, DA, Thrasher, TN, Keil, LC, Ramsay, DJ, Mechanism of inhibition of renin response to hypotension by atrial natriuretic factor. Am J Physiol 257 (1989), R194–R203.
33. 33 Stevens, TL, Burnett, JC Jr, Kinoshita, M, Matsuda, Y, Redfield, MM, A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 95 (1995), 1101–1108.
34. 34 Wada, A, Tsutamoto, T, Matsuda, Y, Kinoshita, M, Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 89 (1994), 2232–2240.
35. 35 Cheng, CP, Onishi, K, Ohte, N, Suzuki, M, Little, WC, Functional effects of endogenous bradykinin in congestive heart failure. J Am Coll Cardiol 31 (1998), 1679–1686.
36. 36 Nishikimi, T, Saito, Y, Kitamura, K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26 (1995), 1424–1431.
37. 37 Rosenkranz, AC, Dusting, GJ, Ritchie, RH, Hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes. Clin Exp Pharmacol Physiol 26 (1999), 519–521.
38. 38 Kurisu, S, Ozono, R, Oshima, T, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41 (2003), 99–107.
39. 39 Leong, PK, Zhang, Y, Yang, LE, Holstein-Rathlou, NH, McDonough, AA, Diuretic response to acute hypertension is blunted during angiotensin II clamp. Am J Physiol Regul Integr Comp Physiol 283 (2002), R837–R842.
40. 40 Minami, K, Segawa, K, Uezono, Y, et al. Adrenomedullin inhibits the pressor effects and decrease in renal blood flow induced by norepinephrine or angiotensin II in anesthetized rats. Jpn J Pharmacol 86 (2001), 159–164.
41. 41 Autelitano, DJ, Ridings, R, Pipolo, L, Thomas, WG, Adrenomedullin inhibits angiotensin AT1A receptor expression and function in cardiac fibroblasts. Regul Pept 112 (2003), 131–137.
42. 42 Charles, CJ, Lainchbury, JG, Nicholls, MG, et al. Adrenomedullin and the renin-angiotensin-aldosterone system. Regul Pept 112 (2003), 41–49.
43. 43 Rubinstein, I, Müns, G, Zucker, IH, Plasma exudation in conscious dogs with experimental heart failure. Basic Res Cardiol 89 (1994), 487–498.
44. 44 Campbell, DJ, The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28 (2001), 1060–1065.
45. 45 Eiskjaer, H, Bagger, JP, Danielsen, H, et al. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol 33 (1991), 61–74.
46. 46 Hirooka, Y, Takeshita, A, Imaizumi, T, et al. Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation 82 (1990), 147–153.
47. 47 Edvinsson, ML, Uddman, E, Edvinsson, L, Andersson, SE, Brain natriuretic peptide is a potent vasodilator in aged human microcirculation and shows a blunted response in heart failure patients. J Geriatr Cardiol 11 (2014), 50–56.
48. 48 Hoffman, A, Grossman, E, Keiser, HR, Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure. Am J Hypertens 4 (1991), 597–601.
49. 49 Nicholls, MG, Lainchbury, JG, Lewis, LK, et al. Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides 22 (2001), 1745–1752.
50. 50 Charloux, A, Piquard, F, Doutreleau, S, Brandenberger, G, Geny, B, Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33 (2003), 769–778.
51. 51 Baerts, L, Gomez, N, Vanderheyden, M, De Meester, I, Mc Entee, K, Possible mechanisms for brain natriuretic peptide resistance in heart failure with a focus on interspecies differences and canine BNP biology. Vet J 194 (2012), 34–39.
52. 52 Brandt, RR, Wright, RS, Redfield, MM, Burnett, JC Jr, Atrial natriuretic peptide in heart failure. J Am Coll Cardiol 22:suppl A (1993), 86A–92A.
53. 53 Lee, EY, Humphreys, MH, Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol 271 (1996), F3–F6.
54. 54 Cruden, NL, Fox, KA, Ludlam, CA, Johnston, NR, Newby, DE, Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension 44 (2004), 913–918.
55. 55 Rademaker, MT, Charles, CJ, Espiner, EA, Nicholls, MG, Richards, AM, Kosoglou, T, Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond) 91 (1996), 283–291.
56. 56 Wilkinson, IB, McEniery, CM, Bongaerts, KH, MacCallum, H, Webb, DJ, Cockcroft, JR, Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol 52 (2001), 159–164.
57. 57 Knecht, M, Pagel, I, Langenickel, T, et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci 71 (2002), 2701–2712.
58. 58 Bayés-Genís, A, Barallat, J, Galán, A, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65 (2015), 657–665.
59. 59 Vodovar, N, Séronde, M-F, Laribi, S, et al. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail 3 (2015), 629–636.
60. 60 Wegner, M, Hirth-Dietrich, C, Stasch, JP, Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure. Cardiovasc Res 31 (1996), 891–898.
61. 61 Trippodo, NC, Gabel, RA, Harvey, CM, Asaad, MM, Rogers, WL, Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats. J Cardiovasc Pharmacol 18 (1991), 308–316.
62. 62 Martin, FL, Stevens, TL, Cataliotti, A, et al. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int 67 (2005), 1723–1730.
63. 63 Maric, C, Zheng, W, Walther, T, Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol 103 (2006), 149–156.
64. 64 Farina, NK, Johnston, CI, Burrell, LM, Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens 18 (2000), 749–755.
65. 65 Newaz, M, Yousefipour, Z, Oyekan, A, Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure. Ren Fail 32 (2010), 384–390.
66. 66 Tanaka, Y, Nagai, M, Date, T, et al. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 27 (2004), 865–875.
67. 67 Chen, HH, Lainchbury, JG, Harty, GJ, Burnett, JC Jr, Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 105 (2002), 999–1003.
68. 68 Beierwaltes, WH, Carretero, OA, Scicli, AG, Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol 255 (1988), F408–F414.
69. 69 Edelbauer, H, Lechner, SG, Mayer, M, Scholze, T, Boehm, S, Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin. J Neurochem 93 (2005), 1110–1121.
70. 70 Rhaleb, NE, Yang, XP, Carretero, OA, The kallikrein-kinin system as a regulator of cardiovascular and renal function. Compr Physiol 1 (2011), 971–993.
71. 71 Pons, S, Griol-Charhbili, V, Heymes, C, et al. Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur J Heart Fail 10 (2008), 343–351.
72. 72 Rademaker, MT, Charles, CJ, Nicholls, MG, Richards, AM, Hemodynamic, hormonal, and renal actions of adrenomedullin 2 in experimental heart failure. Circ Heart Fail 1 (2008), 134–142.
73. 73 Wang, XF, Shao, Y, Chen, SW, et al. Amelioration of cardiac function in chronic myocardial infarcted rats following administration of vector pcDNA3.1AM. Clin Exp Pharmacol Physiol 34 (2007), 861–865.
74. 74 Nakamura, R, Kato, J, Kitamura, K, et al. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation 110 (2004), 426–431.
75. 75 Kasama, S, Toyama, T, Hatori, T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 49 (2007), 667–674.
76. 76 Cataliotti, A, Tonne, JM, Bellavia, D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 123 (2011), 1297–1305.
77. 77 Florkowski, CM, Richards, AM, Espiner, EA, Yandle, TG, Sybertz, E, Frampton, CM, Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci (Lond) 92 (1997), 255–260.
78. 78 Mercure, C, Yogi, A, Callera, GE, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circulation Res 103 (2008), 1319–1326.
79. 79 Velez, JC, Ryan, KJ, Harbeson, CE, et al. Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension 53 (2009), 790–797.
80. 80 Ferrario, CM, Smith, RD, Brosnihan, B, et al. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens 15 (2002), 557–564.
81. 81 Chappell, MC, Allred, AJ, Ferrario, CM, Pathways of angiotensin-(1-7) metabolism in the kidney. Nephrol Dial Transplant 16:suppl 1 (2001), 22–26.
82. 82 Richards, AM, Wittert, GA, Crozier, IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 11 (1993), 407–416.
83. 83 Richards, AM, Wittert, GA, Espiner, EA, Yandle, TG, Ikram, H, Frampton, C, Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 71 (1992), 1501–1507.
84. 84 Schmitt, F, Martinez, F, Ikeni, A, et al. Acute renal effects of neutral endopeptidase inhibition in humans. Am J Physiol 267 (1994), F20–F27.
85. 85 Miners, JS, Palmer, JC, Tayler, H, et al. Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Front Aging Neurosci, 6, 2014, 238.
86. 86 Witherow, FN, Helmy, A, Webb, DJ, Fox, KA, Newby, DE, Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104 (2001), 2177–2181.
87. 87 Amann, K, Gassmann, P, Buzello, M, et al. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney Int 58 (2000), 153–161.
88. 88 Cockcroft, JR, Sciberras, DG, Goldberg, MR, Ritter, JM, Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22 (1993), 579–584.
89. 89 Campbell, DJ, Kladis, A, Valentijn, AJ, Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 26 (1995), 233–240.
90. 90 McDonald, KM, Mock, J, D'Aloia, A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91 (1995), 2043–2048.
91. 91 Zhu, YC, Zhu, YZ, Gohlke, P, Stauss, HM, Unger, T, Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol 80 (1997), 110A–117A.
92. 92 Bouaziz, H, Joulin, Y, Safar, M, Benetos, A, Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition. Br J Pharmacol 113 (1994), 717–722.
93. 93 Hartman, JC, Wall, TM, Hullinger, TG, Shebuski, RJ, Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 21 (1993), 996–1003.
94. 94 Kokkonen, JO, Lindstedt, KA, Kuoppala, A, Kovanen, PT, Kinin-degrading pathways in the human heart. Trends Cardiovasc Med 10 (2000), 42–45.
95. 95 Ong, HT, Ong, LM, Ho, JJ, Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials. ISRN Cardiol, 2013, 2013, 478597.
96. 96 Baker, WL, Coleman, CI, Kluger, J, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 151 (2009), 861–871.
97. 97 Cheng, J, Zhang, W, Zhang, X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174 (2014), 773–785.
98. 98 Savarese, G, Costanzo, P, Cleland, JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 61 (2013), 131–142.
99. 99 Heran, BS, Musini, VM, Bassett, K, Taylor, RS, Wright, JM, Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev, 4, 2012 CD003040.
100. 100 Flather, MD, Yusuf, S, Køber, L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 (2000), 1575–1581.
101. 101 CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
102. 102 SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
103. 103 Cohn, JN, Tognoni, G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001), 1667–1675.
104. 104 Granger, CB, McMurray, JJ, Yusuf, S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003), 772–776.
105. 105 Pitt, B, Poole-Wilson, PA, Segal, R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000), 1582–1587.
106. 106 Dickstein, K, Kjekshus, J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002), 752–760.
107. 107 Pfeffer, MA, McMurray, JJ, Velazquez, EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003), 1893–1906.
108. 108 Takahama, K, Araki, T, Fuchikami, J, Kohjimoto, Y, Miyata, T, Studies on the magnitude and the mechanism of cough potentiation by angiotensin-converting enzyme inhibitors in guinea-pigs: involvement of bradykinin in the potentiation. J Pharm Pharmacol 48 (1996), 1027–1033.
109. 109 Baş, M, Greve, J, Stelter, K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372 (2015), 418–425.
110. 110 Grilo, A, Sáez-Rosas, MP, Santos-Morano, J, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 21 (2011), 10–17.
111. 111 Davie, AP, McMurray, JJ, Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34 (1999), 457–460.
112. 112 Keidar, S, Kaplan, M, Gamliel-Lazarovich, A, ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res 73 (2007), 463–469.
113. 113 Sukumaran, V, Veeraveedu, PT, Gurusamy, N, et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 351 (2012), 208–219.
114. 114 Goulter, AB, Goddard, MJ, Allen, JC, Clark, KL, ACE2 gene expression is up-regulated in the human failing heart. BMC Med, 2, 2004, 19.
115. 115 Epelman, S, Tang, WH, Chen, SY, Van Lente, F, Francis, GS, Sen, S, Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52 (2008), 750–754.
116. 116 Erdös, EG, Jackman, HL, Brovkovych, V, Tan, F, Deddish, PA, Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 34 (2002), 1569–1576.
117. 117 Zhong, J, Basu, R, Guo, D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122 (2010), 717–728.
118. 118 McKinney, CA, Fattah, C, Loughrey, CM, Milligan, G, Nicklin, SA, Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin Sci (Lond) 126 (2014), 815–827.
119. 119 Thai, H, Wollmuth, J, Goldman, S, Gaballa, M, Angiotensin subtype 1 receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. J Pharmacol Exp Ther 307 (2003), 1171–1178.
120. 2 receptor activation induces natriuresis and lowers blood pressure. Circ Res 115 (2014), 388–399.
121. 121 Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), 1810–1852.
122. 122 McMurray, JJ, Adamopoulos, S, Anker, SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
123. 123 Krum, H, van Veldhuisen, DJ, Funck-Brentano, C, et al. Effect on mode of death of heart failure treatment started with bisoprolol followed by enalapril, compared to the opposite order: results of the randomized CIBIS III trial. Cardiovasc Ther 29 (2011), 89–98.
124. 124 Shefer, G, Marcus, Y, Knoll, E, et al. Angiotensin 1-7 is a negative modulator of aldosterone secretion in vitro and in vivo. Hypertension 68 (2016), 378–384.
125. 125 Xu, C, Ding, W, Zhang, M, Gu, Y, Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease. Nephrology (Carlton) 18 (2013), 761–769.
126. 126 Yousif, MH, Dhaunsi, GS, Makki, BM, Qabazard, BA, Akhtar, S, Benter, IF, Characterization of angiotensin-(1–7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res 66 (2012), 269–275.
127. 127 Li, Y, Wu, J, He, Q, et al. Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertens Res 32 (2009), 369–374.
128. 128 Benter, IF, Yousif, MH, Cojocel, C, Al-Maghrebi, M, Diz, DI, Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292 (2007), H666–H672.
129. 129 Papinska, AM, Mordwinkin, NM, Meeks, CJ, Jadhav, SS, Rodgers, KE, Angiotensin-(1–7) administration benefits cardiac, renal and progenitor cell function in db/db mice. Br J Pharmacol, 2015 published online Jun 15. http://dx.doi.org/10.1111/bph.13225.
130. 130 Mori, J, Patel, VB, Ramprasath, T, et al. Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306 (2014), F812–F821.
131. 131 Taal, MW, Nenov, VD, Wong, W, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12 (2001), 2051–2059.
132. 132 Wang, T, Takabatake, T, Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. Hypertens Res 28 (2005), 611–618.
133. 133 Trippodo, NC, Fox, M, Monticello, TM, Panchal, BC, Asaad, MM, Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34 (1999), 782–790.
134. 134 Rademaker, MT, Charles, CJ, Espiner, EA, Nicholls, MG, Richards, AM, Kosoglou, T, Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 31 (1998), 116–125.
135. 135 Troughton, RW, Rademaker, MT, Powell, JD, et al. Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 36 (2000), 523–530.
136. 136 Trippodo, NC, Robl, JA, Asaad, MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 275 (1995), 745–752.
137. 137 Rouleau, JL, Pfeffer, MA, Stewart, DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356 (2000), 615–620.
138. 138 Fryer, RM, Segreti, J, Banfor, PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 153 (2008), 947–955.
139. 139 Kostis, JB, Packer, M, Black, HR, Schmieder, R, Henry, D, Levy, E, Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens 17 (2004), 103–111.
140. 140 Packer, M, Califf, RM, Konstam, MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 106 (2002), 920–926.
141. 141 Nanas, JN, Alexopoulos, G, Anastasiou-Nana, MI, et al. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 36 (2000), 2090–2095.
142. 142 The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 19 (1998), 481–489.
143. 143 Møller, JE, Dahlström, U, Gøtzsche, O, et al. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the optimal trial in myocardial infarction with angiotensin ii antagonist losartan (OPTIMAAL) echocardiographic substudy. Am Heart J 147 (2004), 494–501.
144. 144 Konstam, MA, Neaton, JD, Dickstein, K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009), 1840–1848.
145. 145 Gu, J, Noe, A, Chandra, P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50 (2010), 401–414.
146. 146 Kario, K, Sun, N, Chiang, FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 63 (2014), 698–705.
147. 147 Bloch, MJ, Basile, JN, Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens (Greenwich) 12 (2010), 809–812.
148. 148 Ruilope, LM, Dukat, A, Böhm, M, Lacourcière, Y, Gong, J, Lefkowitz, MP, Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (2010), 1255–1266.
149. 149 Hegde, LG, Yu, C, Renner, T, et al. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. J Cardiovasc Pharmacol 57 (2011), 495–504.
150. 150 Maggioni, AP, Anand, I, Gottlieb, SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002), 1414–1421.
151. 151 McMurray, J, Packer, M, Desai, A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J 36 (2015), 434–439.
152. 152 Packer, M, McMurray, JJ, Desai, AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
153. 153 Baranello, RJ, Bharani, KL, Padmaraju, V, et al. Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res 12 (2015), 32–46.
154. 154 Miners, JS, Kehoe, P, Love, S, Neprilysin protects against cerebral amyloid angiopathy and Aβ-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol 21 (2011), 594–605.
155. 155 Guan, H, Liu, Y, Daily, A, et al. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res 87 (2009), 1462–1473.
156. 156 Zou, K, Yamaguchi, H, Akatsu, H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 27 (2007), 8628–8635.
157. 157 Hemming, ML, Selkoe, DJ, Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280 (2005), 37644–37650.
158. 158 Marr, RA, Hafez, DM, Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance. Front Aging Neurosci, 6, 2014, 187.
159. 159 Park, MH, Lee, JK, Choi, S, et al. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice. Brain Res 1529 (2013), 113–124.
160. 160 Feldman, AM, Haller, JA, DeKosky, ST, Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 315 (2016), 25–26.
161. 161 Vodovar, N, Paquet, C, Mebazaa, A, Launay, JM, Hugon, J, Cohen-Solal, A, Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. Eur Heart J 36 (2015), 902–905.
162. 162 Kehoe, PG, Wilcock, GK, Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet Neurol 6 (2007), 373–378.
163. 163 Bloch, S, Obari, D, Girouard, H, Angiotensin and neurovascular coupling: beyond hypertension. Microcirculation 22 (2015), 159–167.
164. 164 Wharton, W, Stein, JH, Korcarz, C, et al. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis 32 (2012), 147–156.
165. 165 Dong, YF, Kataoka, K, Tokutomi, Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 25 (2011), 2911–2920.
166. 166 Ye, R, Hu, Y, Yao, A, et al. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis. Int J Clin Pract 69 (2015), 674–681.
167. 167 Wang, J, Ho, L, Chen, L, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117 (2007), 3393–3402.
168. 168 Fournier, A, Oprisiu-Fournier, R, Serot, JM, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 9 (2009), 1413–1431.
169. 169 Langenickel, TH, Tsubouchi, C, Ayalasomayajula, S, et al. The effect of LCZ696 on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81 (2015), 878–890.
170. 170 Moro, ML, Giaccone, G, Lombardi, R, et al. APP mutations in the Ab coding region are associated with abundant cerebral deposition of Ab38. Acta Neuropathol 124 (2012), 809–821.
171. 171 Packer, M, Kicking the tires of a heart failure trial: the response to the approval of sacubitril/valsartan in the US. Eur J Heart Fail, 2016 10.1002/ejhf.623 published online Aug 10.
172. 172 McMurray, JJ, Packer, M, Solomon, SD, Neprilysin inhibition for heart failure. N Engl J Med 371 (2014), 2336–2337.